nach oben

Drugs & Aging

Erschienen in:

01.12.2004 | Review Article

The Treatment of Chronic Constipation in Elderly People

An Update

verfasst von: Wanda Bosshard, Rebecca Dreher, Jean-François Schnegg, Dr Christophe J. Büla

Erschienen in: Drugs & Aging | Ausgabe 14/2004

Einloggen, um Zugang zu erhalten

Abstract

Constipation is a common problem in elderly persons, with prevalence ranging from 15% to 20% in the community-dwelling elderly population and up to 50% in some studies of nursing home residents. In these patients, constipation results from a combination of risk factors, such as reduced fibre and fluid intake, decreased physical activity resulting from chronic diseases and multiple medications. Despite the high prevalence of constipation, there is surprisingly little evidence available on which to base management decisions of this common condition.

Increased fluid intake, regular physical activity and high fibre intake are usually proposed as first step nonpharmacological measures. However, adherence to these measures is limited and pharmacological treatment is frequently required. Data are too limited, especially in elderly persons, to formally recommend one class of laxatives over another or one agent over another within each class. However, bulk-forming and osmotic laxatives are usually recommended as first-line agents, even though data on their effectiveness are limited. The need to maintain good hydration is a limitation in the use of bulk-forming laxatives, in particular, in frail elderly patients. In these patients, polyethylene glycol, an osmotic agent, is an attractive alternative. In addition, it has been shown to relieve faecal impaction in frail patients with neurological disease. Its cost and potential danger in patients at high risk for aspiration is, however, a limitation. Stimulant laxatives are considered mainly as an intermittent treatment in patients who do not respond to bulk-forming or osmotic laxatives.

Several promising compounds such as the new serotonin 5-HT₄ receptor agonists (tegaserod, prucalopride) and neurotrophin-3 (NT3) have not been adequately tested in older individuals. They are not routinely used and their role in the management of constipation in these patients will be more precisely defined in the future. Other treatment options are available (acupuncture, biofeedback, botulinum toxin and surgery), but experience with these interventions in elderly patients is limited and their indications in this population remain to be clarified.

Management of constipation in elderly persons depends largely on experience and beliefs. Several new compounds seem promising but will need to be specifically tested in this population before being recommended.

Wanitschke R, Goerg KJ, Loew D. Differential therapy of constipation: a review. Int J Clin Pharmacol Ther 2003 Jan; 41(1): 14–21PubMed

Sandler RS, Drossman DA. Bowel habits in young adults not seeking health care. Dig Dis Sci 1987 Aug; 32(8): 841–5PubMedCrossRef

Harari D, Gurwitz JH, Avorn J, et al. Constipation: assessment and management in an institutionalized elderly population. J Am Geriatr Soc 1994 Sep; 42(9): 947–52PubMed

Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999 Sep; 45Suppl. 2: II43–7PubMedCrossRef

Stewart WF, Liberman JN, Sandler RS, et al. Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features. Am J Gastroenterol 1999 Dec; 94(12): 3530–40PubMedCrossRef

Talley NJ, Weaver AL, Zinsmeister AR, et al. Functional constipation and outlet delay: a population-based study. Gastroenterology 1993 Sep; 105(3): 781–90PubMed

Donald IP, Smith RG, Cruikshank JG, et al. A study of constipation in the elderly living at home. Gerontology 1985; 31(2): 112–8PubMedCrossRef

Whitehead WE, Drinkwater D, Cheskin LJ, et al. Constipation in the elderly living at home: definition, prevalence, and relationship to lifestyle and health status. J Am Geriatr Soc 1989 May; 37(5): 423–9PubMed

Harari D, Gurwitz JH, Avorn J, et al. Bowel habit in relation to age and gender: findings from the National Health Interview Survey and clinical implications. Arch Intern Med 1996 Feb 12; 156(3): 315–20PubMedCrossRef

10.

Pare P, Ferrazzi S, Thompson WG, et al. An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol 2001 Nov; 96(11): 3130–7PubMedCrossRef

11.

Sonnenberg A, Koch TR. Physician visits in the United States for constipation: 1958 to 1986. Dig Dis Sci 1989 Apr; 34(4): 606–11PubMedCrossRef

12.

Johanson JF, Sonnenberg A, Koch TR. Clinical epidemiology of chronic constipation. J Clin Gastroenterol 1989 Oct; 11(5): 525–36PubMedCrossRef

13.

Talley NJ, Fleming KC, Evans JM, et al. Constipation in an elderly community: a study of prevalence and potential risk factors. Am J Gastroenterol 1996 Jan; 91(1): 19–25PubMed

14.

Campbell AJ, Busby WJ, Horwath CC. Factors associated with constipation in a community based sample of people aged 70 years and over. J Epidemiol Community Health 1993 Feb; 47(1): 23–6PubMedCrossRef

15.

Dukas L, Willett WC, Giovannucci EL. Association between physical activity, fiber intake, and other lifestyle variables and constipation in a study of women. Am J Gastroenterol 2003 Aug; 98(8): 1790–6PubMedCrossRef

16.

Rouse M, Chapman N, Mahapatra M, et al. An open, randomised, parallel group study of lactulose versus ispaghula in the treatment of chronic constipation in adults. Br J Clin Pract 1991; 45(1): 28–30PubMed

17.

Monane M, Avorn J, Beers MH, et al. Anticholinergic drug use and bowel function in nursing home patients. Arch Intern Med 1993 Mar 8; 153(5): 633–8PubMedCrossRef

18.

Lamy PP, Krug BH. Review of laxative utilization in a skilled nursing facility. J Am Geriatr Soc 1978 Dec; 26(12): 544–9PubMed

19.

Robson KM, Kiely DK, Lembo T. Development of constipation in nursing home residents. Dis Colon Rectum 2000 Jul; 43(7): 940–3PubMedCrossRef

20.

Harari D, Gurwitz JH, Avorn J, et al. Correlates of regular laxative use by frail elderly persons. Am J Med 1995 Nov; 99(5): 513–8PubMedCrossRef

21.

O’Keefe EA, Talley NJ, Zinsmeister AR, et al. Bowel disorders impair functional status and quality of life in the elderly: a population-based study. J Gerontol A Biol Sci Med Sci 1995 Jul; 50(4): M184–9PubMedCrossRef

22.

Wolfsen CR, Barker JC, Mitteness LS. Constipation in the daily lives of frail elderly people. Arch Fam Med 1993 Aug; 2(8): 853–8PubMedCrossRef

23.

Irvine EJ, Ferrazzi S, Pare P, et al. Health-related quality of life in functional GI disorders: focus on constipation and resource utilization. Am J Gastroenterol 2002 Aug; 97(8): 1986–93PubMedCrossRef

24.

Petticrew M, Watt I, Sheldon T. Systematic review of the effectiveness of laxatives in the elderly. Health Technol Assess 1997; I(13): 1–52

25.

Tedesco FJ, DiPiro JT. Laxative use in constipation. American College of Gastroenterology’s Committee on FDA-Related Matters. Am J Gastroenterol 1985 Apr; 80(4): 303–9PubMed

26.

Camilleri M, Lee JS, Viramontes B, et al. Insights into the pathophysiology and mechanisms of constipation, irritable bowel syndrome, and diverticulosis in older people. J Am Geriatr Soc 2000 Sep; 48(9): 1142–50PubMed

27.

Orr WC, Chen CL. Aging and neural control of the GI tract: IV. Clinical and physiological aspects of gastrointestinal motility and aging. Am J Physiol 2002 Dec; 283(6): G1226–31

28.

McHugh SM, Diamant NE. Effect of age, gender, and parity on anal canal pressures: contribution of impaired anal sphincter function to fecal incontinence. Dig Dis Sci 1987 Jul; 32(7): 726–36PubMedCrossRef

29.

Akervall S, Nordgren S, Fasth S, et al. The effects of age, gender, and parity on rectoanal functions in adults. Scand J Gastroenterol 1990 Dec; 25(12): 1247–56PubMedCrossRef

30.

Abyad A, Mourad F. Constipation: common-sense care of the older patient. Geriatrics 1996 Dec; 51(12): 28–34PubMed

31.

Talley NJ, Jones M, Nuyts G, et al. Risk factors for chronic constipation based on a general practice sample. Am J Gastroenterol 2003 May; 98(5): 1107–11PubMedCrossRef

32.

Jones RH, Tait CL. Gastrointestinal side-effects of NSAIDs in the community. Br J Clin Pract 1995 Mar; 49(2): 67–70PubMed

33.

Bjornsson ES, Chey WD, Hooper F, et al. Impaired gastrocolonic response and peristaltic reflex in slow-transit constipation: role of 5-HT(3) pathways. Am J Physiol 2002 Aug; 283(2): G400–7

34.

Bassotti G, Imbimbo BP, Betti C, et al. Impaired colonic motor response to eating in patients with slow-transit constipation. Am J Gastroenterol 1992 Apr; 87(4): 504–8PubMed

35.

Tomita R, Fujisaki S, Ikeda T, et al. Role of nitric oxide in the colon of patients with slow-transit constipation. Dis Colon Rectum 2002 May; 45(5): 593–600PubMedCrossRef

36.

Tomita R, Tanjoh K, Fujisaki S, et al. Regulation of the enteric nervous system in the colon of patients with slow transit constipation. Hepatogastroenterology 2002 Nov; 49(48): 1540–4PubMed

37.

Sjolund K, Fasth S, Ekman R, et al. Neuropeptides in idiopathic chronic constipation (slow transit constipation). Neurogastroenterol Motil 1997 Sep; 9(3): 143–50PubMedCrossRef

38.

Rao SS, Welcher KD, Leistikow JS. Obstructive defecation: a failure of rectoanal coordination. Am J Gastroenterol 1998 Jul; 93(7): 1042–50PubMedCrossRef

39.

Jones MP, Talley NJ, Nuyts G, et al. Lack of objective evidence of efficacy of laxatives in chronic constipation. Dig Dis Sci 2002 Oct; 47(10): 2222–30PubMedCrossRef

40.

Tramonte SM, Brand MB, Mulrow CD, et al. The treatment of chronic constipation in adults: a systematic review. J Gen Intern Med 1997 Jan; 12(1): 15–24PubMedCrossRef

41.

DiPalma JA, DeRidder PH, Orlando RC, et al. A randomized, placebo-controlled, multicenter study of the safety and efficacy of a new polyethylene glycol laxative. Am J Gastroenterol 2000 Feb; 95(2): 446–50PubMedCrossRef

42.

Corazziari E, Badiali D, Bazzocchi G, et al. Long term efficacy, safety, and tolerability of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation. Gut 2000 Apr; 46(4): 522–6PubMedCrossRef

43.

Attar A, Lemann M, Ferguson A, et al. Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation. Gut 1999 Feb; 44(2): 226–30PubMedCrossRef

44.

Chaussade S, Minic M. Comparison of efficacy and safety of two doses of two different polyethylene glycol-based laxatives in the treatment of constipation. Aliment Pharmacol Ther 2003 Jan; 17(1): 165–72PubMedCrossRef

45.

Eichhorn TE, Oertel WH. Macrogol 3350/electrolyte improves constipation in Parkinson’s disease and multiple system atrophy. Mov Disord 2001 Nov; 16(6): 1176–7PubMedCrossRef

46.

Lefkowitz MP, Rueegg PC, Shi Y, et al. Validation of a global relief measure in two clinical trials of irritable bowel syndrome with tegaserod [abstract]. Gastroenterology 2000; 118Suppl 2 (Pt 1): A145CrossRef

47.

Tonini M. Recent advances in the pharmacology of gastrointestinal prokinetics. Pharmacol Res 1996 Apr; 33(4–5): 217–26PubMedCrossRef

48.

Kellow J, Lee OY, Chang FY, et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003 May; 52(5): 671–6PubMedCrossRef

49.

Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001 Oct; 15(10): 1655–66PubMedCrossRef

50.

Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002 Nov; 16(11): 1877–88PubMedCrossRef

51.

Coremans G, Kerstens R, De Pauw M, et al. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief: results of a double-blind, placebo-controlled clinical trial. Digestion 2003; 67(1–2): 82–9PubMedCrossRef

52.

Verne GN, Eaker EY, Davis RH, et al. Colchicine is an effective treatment for patients with chronic constipation: an open-label trial. Dig Dis Sci 1997 Sep; 42(9): 1959–63PubMedCrossRef

53.

Verne GN, Davis RH, Robinson ME, et al. Treatment of chronic constipation with colchicine: randomized, double-blind, placebo-controlled, crossover trial. Am J Gastroenterol 2003 May; 98(5): 1112–6PubMed

54.

Soffer EE, Metcalf A, Launspach J. Misoprostol is effective treatment for patients with severe chronic constipation. Dig Dis Sci 1994 May; 39(5): 929–33PubMedCrossRef

55.

Roarty TP, Weber F, Soykan I, et al. Misoprostol in the treatment of chronic refractory constipation: results of a long-term open label trial. Aliment Pharmacol Ther 1997 Dec; 11(6): 1059–66PubMedCrossRef

56.

Chalazonitis A, Pham TD, Rothman TP, et al. Neurotrophin-3 is required for the survival-differentiation of subsets of developing enteric neurons. J Neurosci 2001 Aug 1; 21(15): 5620–36PubMed

57.

Parkman HP, Rao SS, Reynolds JC, et al. Neurotrophin-3 improves functional constipation. Am J Gastroenterol 2003 Jun; 98(6): 1338–47PubMedCrossRef

58.

Towers AL, Burgio KL, Locher JL, et al. Constipation in the elderly: influence of dietary, psychological, and physiological factors. J Am Geriatr Soc 1994 Jul; 42(7): 701–6PubMed

59.

Lindeman RD, Romero LJ, Liang HC, et al. Do elderly persons need to be encouraged to drink more fluids? J Gerontol A Biol Sci Med Sci 2000 Jul; 55(7): M361–5PubMedCrossRef

60.

Meshkinpour H, Selod S, Movahedi H, et al. Effects of regular exercise in management of chronic idiopathic constipation. Dig Dis Sci 1998 Nov; 43(11): 2379–83PubMedCrossRef

61.

Petticrew M, Rodgers M, Booth A. Effectiveness of laxatives in adults. Qual Health Care 2001 Dec; 10(4): 268–73PubMedCrossRef

62.

Golzarian J, Scott Jr HW, Richards WO. Hypermagnesemiainduced paralytic ileus. Dig Dis Sci 1994 May; 39(5): 1138–42PubMedCrossRef

63.

Muller-Lissner SA. Effect of wheat bran on weight of stool and gastrointestinal transit time: a meta analysis. BMJ Clin Res 1988 Feb 27; 296(6622): 615–7CrossRef

64.

Francis CY, Whorwell PJ. Bran and irritable bowel syndrome: time for reappraisal. Lancet 1994 Jul 2; 344(8914): 39–40PubMedCrossRef

65.

Chokhavatia S, Philipps T, Anuras S. Comparative laxation of calcium polycarbophil with psyllium muciloid in an ambulatory geriatric population. Curr Ther Res Clin Exp 1988; 44: 1013–9

66.

Ashraf W, Pfeiffer RF, Park F, et al. Constipation in Parkinson’s disease: objective assessment and response to psyllium. Mov Disord 1997 Nov; 12(6): 946–51PubMedCrossRef

67.

McRorie JW, Daggy BP, Morel JG, et al. Psyllium is superior to docusate sodium for treatment of chronic constipation. Aliment Pharmacol Ther 1998 May; 12(5): 491–7PubMedCrossRef

68.

Voderholzer WA, Schatke W, Muhldorfer BE, et al. Clinical response to dietary fiber treatment of chronic constipation. Am J Gastroenterol 1997 Jan; 92(1): 95–8PubMed

69.

Kinnunen O, Salokannel J. Comparison of the effects of magnesium hydroxide and a bulk laxative on lipids, carbohydrates, vitamins A and E, and minerals in geriatric hospital patients in the treatment of constipation. J Int Med Res 1989 Sep; 17(5): 442–54PubMed

70.

Kinnunen O, Salokannel J. Constipation in elderly long-stay patients: its treatment by magnesium hydroxide and bulk-laxative. Ann Clin Res 1987; 19(5): 321–3PubMed

71.

Lederle FA, Busch DL, Mattox KM, et al. Cost-effective treatment of constipation in the elderly: a randomized double-blind comparison of sorbitol and lactulose. Am J Med 1990 Nov; 89(5): 597–601PubMedCrossRef

72.

Passmore AP, Wilson-Davies K, Stoker C, et al. Chronic constipation in long stay elderly patients: a comparison of lactulose and a senna-fibre combination. BMJ 1993 Sep 25; 307(6907): 769–71PubMedCrossRef

73.

Christie AH, Culbert P, Guest JF. Economic impact of low dose polyethylene glycol 3350 plus electrolytes compared with lactulose in the management of idiopathic constipation in the UK. Pharmacoeconomics 2002; 20(1): 49–60PubMedCrossRef

74.

Culbert P, Gillett H, Ferguson A. Highly effective oral therapy (polyethylene glycol/electrolyte solution) for faecal impaction and severe constipation. Clin Drugs Invest 1998; 16(5): 355–60CrossRef

75.

Argent A, Hatherill M, Reynolds L, et al. Fulminant pulmonary oedema after administration of a balanced electrolyte polyethylene glycol solution. Arch Dis Child 2002 Mar; 86(3): 209PubMedCrossRef

76.

Paap CM, Ehrlich R. Acute pulmonary edema after polyethylene glycol intestinal lavage in a child. Ann Pharmacother 1993 Sep; 27(9): 1044–7PubMed

77.

Marschall HU, Bartels F. Life-threatening complications of nasogastric administration of polyethylene glycol-electrolyte solutions (Golytely) for bowel cleansing. Gastrointest Endosc 1998 May; 47(5): 408–10PubMedCrossRef

78.

Lembo A, Camilleri M. Chronic constipation. N Engl J Med 2003 Oct 2; 349(14): 1360–8PubMedCrossRef

79.

Joo JS, Ehrenpreis ED, Gonzalez L, et al. Alterations in colonic anatomy induced by chronic stimulant laxatives: the cathartic colon revisited. J Clin Gastroenterol 1998 Jun; 26(4): 283–6PubMedCrossRef

80.

Wald A. Is chronic use of stimulant laxatives harmful to the colon? J Clin Gastroenterol 2003 May; 36(5): 386–9PubMedCrossRef

81.

Xing JH, Soffer EE. Adverse effects of laxatives. Dis Colon Rectum 2001 Aug; 44(8): 1201–9PubMedCrossRef

82.

Kinnunen O, Winblad I, Koistinen P, et al. Safety and efficacy of a bulk laxative containing senna versus lactulose in the treatment of chronic constipation in geriatric patients. Pharmacology 1993 Oct; 47: Suppl. 1: 253–5PubMedCrossRef

83.

Badiali D, Marcheggiano A, Pallone F, et al. Melanosis of the rectum in patients with chronic constipation. Dis Colon Rectum 1985 Apr; 28(4): 241–5PubMedCrossRef

84.

Nascimbeni R, Donato F, Ghirardi M, et al. Constipation, anthranoid laxatives, melanosis coli, and colon cancer: a risk assessment using aberrant crypt foci. Cancer Epidemiol Biomarkers Prev 2002 Aug; 11(8): 753–7PubMed

85.

Nusko G, Schneider B, Schneider I, et al. Anthranoid laxative use is not a risk factor for colorectal neoplasia: results of a prospective case control study. Gut 2000 May; 46(5): 651–5PubMedCrossRef

86.

NHS Center for Reviews and Dissemination. Effectiveness of laxatives in adults. Eff Health Care 2001 Sep; 7(1): 1–12

87.

Williamson J, Coll M, Connolly M. A comparative trial of a new laxative. Nurs Times 1975 Oct 23; 71(43): 1705–7PubMed

88.

MacLennan WJ, Pooler AFWM. A comparison of sodium picosulphate (‘Laxoberal’) with standardised senna (‘Senokot’) in geriatric patients. Curr Med Res Opin 1974; 2(10): 641–7PubMedCrossRef

89.

Bouras EP, Camilleri M, Burton DD, et al. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut 1999 May; 44(5): 682–6PubMedCrossRef

90.

Joslyn A, Stevens M, De Pauw M, et al. Prucalopride is safe and generally well tolerated in elderly patients with chronic constipation [abstract]. Am J Gastroenterol 2000; 95: 2537–8CrossRef

91.

Camilleri M. Review article: tegaserod. Aliment Pharmacol Ther 2001 Mar; 15(3): 277–89PubMedCrossRef

92.

Chey WD. Tegaserod and other serotonergic agents: what is the evidence? Rev Gastroenterol Disord 2003; 3Suppl. 2: S35–40PubMed

93.

Appel-Dingemanse S. Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity. Clin Pharmacokinetics 2002; 41(13): 1021–42CrossRef

94.

Hasler WL, Heldsinger A, Chung OY. Erythromycin contracts rabbit colon myocytes via occupation of motilin receptors. Am J Physiol 1992 Jan; 262 (1 Pt 1): G50–5PubMed

95.

Bellomo-Brandao MA. Use of erythromycin for the treatment of severe chronic constipation in children [abstract]. Braz J Med Biol Res 2003; 36: 1391–6PubMedCrossRef

96.

Sun WM, Hasler WL, Lien HC, et al. Nizatidine enhances the gastrocolonic response and the colonic peristaltic reflex in humans. J Pharmacol Exp Ther 2001 Oct; 299(1): 159–63PubMed

97.

Coulie B, Szarka LA, Camilleri M, et al. Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans. Gastroenterology 2000 Jul; 119(1): 41–50PubMedCrossRef

98.

Zhao H, Liu JP, Liu ZS, et al. Acupuncture for chronic constipation. Cochrane Database Syst Rev 2003; (3): CD004117

99.

Read NW, Timms JM, Barfield LJ, et al. Impairment of defecation in young women with severe constipation. Gastroenterology 1986 Jan; 90(1): 53–60PubMed

100.

Chiotakakou-Faliakou E, Kamm MA, Roy AJ, et al. Biofeedback provides long-term benefit for patients with intractable, slow and normal transit constipation. Gut 1998 Apr; 42(4): 517–21PubMedCrossRef

101.

Verne GN, Hocking MP, Davis RH, et al. Long-term response to subtotal colectomy in colonic inertia. J Gastrointest Surg 2002 Sep; 6(5): 738–44PubMedCrossRef

102.

Aldulaymi BH, Rasmussen OA, Christiansen J. Long-term results of subtotal colectomy for severe slow-transit constipation in patients with normal rectal function. Colorectal Dis 2001; 3(6): 392–5PubMedCrossRef

103.

Nylund G, Oresland T, Fasth S, et al. Long-term outcome after colectomy in severe idiopathic constipation. Colorectal Dis 2001; 3(4): 253–8PubMedCrossRef

104.

Albanese A, Brisinda G, Bentivoglio AR, et al. Treatment of outlet obstruction constipation in Parkinson’s disease with botulinum neurotoxin A. Am J Gastroenterol 2003 Jun; 98(6): 1439–40PubMedCrossRef

105.

Coggrave M, Wiesel PH, Norton C, et al. Management of faecal incontinence and constipation in adults with central neurological diseases. Cochrane Database of Systematic Reviews 2003; (3): CD002115

106.

Goodman ML, Wilkinson S. Laxatives for the management of constipation in palliative care patients. Cochrane Database of Systematic Reviews 2003; (3): CD003448

107.

Klaschik E, Nauck F, Ostgathe C. Constipation: modern laxative therapy. Support Care Cancer 2003 Nov; 11(11): 679–85PubMedCrossRef

108.

Smith S. Evidence-based management of constipation in the oncology patient. Eur J Oncol Nurs 2001 Mar; 5(1): 18–25PubMedCrossRef

109.

Harari D, Gurwitz JH, Minaker KL. Constipation in the elderly. J Am Geriatr Soc 1993 Oct; 41(10): 1130–40PubMed

110.

Romero Y, Evans JM, Fleming KC, et al. Constipation and fecal incontinence in the elderly population. Mayo Clin Proc 1996 Jan; 71: 81–92PubMedCrossRef

111.

Documed. Compendium Suisse des medicants. [online]. Available from URL: http://www.documed.ch. [Accessed 2004 May 21]

112.

Pekmezaris R, Aversa L, Wolf-Klein G, et al. The cost of chronic constipation. J Am Med Dir Assoc 2002; 3: 224–8PubMedCrossRef

113.

Lori F, Schmier J, Kleinman L, et al. Time and economic cost of constipation care in the nursing home. J Am Med Dir Assoc 2002; 3: 215–23CrossRef

Titel: The Treatment of Chronic Constipation in Elderly People
An Update
verfasst von: Wanda Bosshard
Rebecca Dreher
Jean-François Schnegg
Dr Christophe J. Büla
Publikationsdatum: 01.12.2004
Verlag: Springer International Publishing
Erschienen in: Drugs & Aging / Ausgabe 14/2004
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI: https://doi.org/10.2165/00002512-200421140-00002

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 14/2004

Potentially Inappropriate Prescribing in Canada Relative to the US

Rivastigmine in Frontotemporal Dementia

Clodronate